Liraglutide vs Retatrutide
A side-by-side research comparison of Liraglutide and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Liraglutide | Retatrutide |
|---|---|---|
| Full name | Liraglutide (GLP-1 Receptor Agonist / Saxenda) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 3,751 Da | 5,200 Da (approximate) |
| Half-life | 13 hours | 6 days |
| Bioavailability | ~55% (subcutaneous) | High (SubQ) |
| Typical dose | 0.6-3.0 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | Once daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.